

Electronic Supplementary Information

Multicellular aggregation of maltol-modified cells triggered by Fe³⁺ ions

Alexander Ciupa, Paul A. De Bank and Lorenzo Caggiano*

Medicinal Chemistry, Department of Pharmacy and Pharmacology,

University of Bath, Claverton Down, Bath, BA2 7AY, UK.

General Experimental	S2
Preparation of Agarose-Coated Plates	S3
MTS Cell Proliferation Assay.	S4
Cell Aggregation	S5
Optimisation Experiments	S6
Experimental	S7
Acknowledgements.	S12
References	S12
Supplementary Data and Images	
¹ H and ¹³ C NMR Spectra	S13
MTS Assays of maltol hydrazide 6	S17
Fig. S1 HT29 cell Aggregation Experiments	S18
Fig. S2 Extended Aggregation Experiments	S21
Fig. S3 Metal Screen	S22
Fig. S4 HT29 and MDA-MD-231 cell Aggregation Experiments	S23

General Experimental

Chemicals, solvents and reagents used are commercially available and were used without further purification. PE refers to petroleum ether, bp 40-60 °C. TLCs were carried out on Merck Aluminium backed TLC plates Silica Gel 60 F254 and viewed using UV light of wavelength 254 nm and then stained with potassium permanganate. Merck Silica Gel (0.040-0.063 mm) was used for column chromatography. Compounds were loaded as an oil, CH₂Cl₂ solution or dry loaded by adsorption onto silica. Melting points were obtained using a Reichert-Jung heated-stage microscope. Infrared spectra were recorded on a Perkin-Elmer Spectrum RXI FT-IR system and all values are recorded in cm⁻¹.

NMR spectra were obtained on a Bruker Avance III (500 MHz) spectrometer. The chemical shifts are recorded in parts per million (ppm) with reference to tetramethylsilane. The coupling constants *J* are quoted to the nearest 0.5 Hz and are not corrected. The multiplicities are assigned as a singlet (s), doublet (d), triplet (t), doublet of doublets (dd), quartet (q) and multiplet (m). Mass spectra and high resolution mass spectra were obtained on a micrOTOFTM from Bruker Daltonics (Bremen, Germany) coupled with an electrospray source (ESI-TOF) using an autosampler in an Agilent 1100 LC system. Data was processed using external calibration with the Bruker Daltonics software, DataAnalysisTM as part of the overall hardware control software, Compass 1.1TM.

All images were taken on a Leica DMI4000B inverted microscope. Optical density (OD) readings were obtained on a BMG Labtech Fluostar plate reader with NUNC six-well flat bottom plates at room temperature. Data processing and analysis was performed using Microsoft Excel.

Preparation of Agarose-Coated Plates¹

Plates were coated with agarose to prevent cell adhesion during aggregation experiments. The agarose-coated plates were prepared as previously described.¹

Materials

- 1) Agarose (molecular biology grade)
- 2) Tissue culture medium
- 3) Tissue culture-treated six-well plates

Preparation

- 1) 0.9% w/v agarose stock was prepared from 0.9 g agarose in 100 mL of growth-factor free medium.
- 2) The suspension was boiled in a microwave oven to dissolve the agarose and sterilise the solution.
- 3) The solution was pipetted into the plates in a biosafety cabinet. Approximately 2 mL was used per well of a six-well plate.
- 4) Plates were left open in the biosafety cabinet at room temperature, until solidified and used either directly or stored and used later.
- 5) For storage, a small amount of medium was added to each well (approx. 2 mL) to prevent drying out, sealed with a plastic wrap and stored at 4 °C.

MTS Cell Proliferation Assay²

Human cancer cell lines HT29 and MDA-MB-231 were supplied by Cancer Research UK. They were maintained in DMEM with high glucose (4.5 g/L) and 2mM L-glutamine, supplemented with penicillin 100 U/mL, streptomycin 100 µg/mL and foetal bovine serum at 10%. All reagents were supplied by Invitrogen.

The MTS assays of the maltol-hydrazone **6** followed the previously reported procedure,³ and were performed twice with HT29 and once with MDA-MB-231.

A modified MTS protocol, outlined below, was used to determine cell proliferation in the six-well plates of unmodified and maltol-modified HT29 cells in the presence and absence of 50 µM Fe³⁺ after 24, 48 and 72 h incubation.

1. Cells were maintained in 75 cm² tissue culture flasks (Nunc) with a weekly 1:10 split.
2. Three sets of six-well plates were prepared following the procedure outlined in “Cell Aggregation” (next section). After 24 h of agitation, the first set of plates were treated with MTS.
3. 200 µL of MTS reagent was added to each well of a six-well plate containing unmodified and modified HT29 cells with and without 50 µM Fe³⁺.
4. Plates were incubated at 37 °C, in humidified 5% CO₂ in air for 2 h.
5. Optical density readings were taken at 490 nm after 2 h.
6. Means and standard errors were calculated from background corrected OD_{490nm} values.
7. The same steps were taken after 48 h with the second set of six-well plates and again after 72 h with the third set of plates. The whole process was performed in triplicate and the results shown in **Fig. 3**.

Note: This assay is based upon the development of a coloured metabolite from viable cells. Therefore the inhibition of colour development by an active agent does not distinguish between inhibition of cell metabolism *ie* cytostasis and reduction in cell number *ie* cytotoxicity. Nevertheless, this assay provides a very quick and easy first approach for screening test compounds.

Cell Aggregation

Cell aggregation was performed following the procedures previously reported,⁴ but using the maltol-derived hydrazide **6** and HT29 (and MDA-MB-231) cells.

1. Cells were grown to confluence, suspended by brief trypsinisation and washed with room temperature phosphate-buffered saline (PBS). Cells were then resuspended in sodium periodate solution (1 mM in PBS) at 4 °C, incubated in the dark at 4 °C for 10 mins, diluted with PBS and pelleted.
2. The cells were incubated in 10 mL maltol hydrazide **6** solution (100 µM in PBS) for 60 min at room temperature with constant agitation (maximum setting).
3. The cells were then diluted with PBS and pelleted, resuspended in serum free culture medium (DMEM), counted and a stock suspension of 1.0×10^6 cells / mL obtained.
4. 1 mL of this cell suspension was plated into each well of an agarose-coated six-well plate followed by 1 mL of an 100 µM FeCl₃ solution in PBS, giving a final concentration of 5×10^5 cells / mL in 50 µM FeCl₃.
5. The plate was then left at room temperature with constant agitation (maximum setting) for various times and images taken on a Leica DMI400B inverted microscope.
6. The same method was applied for the heteroaggregates with the additional step of fluorescently labelling the HT29 cells green and MDA-MB-231 red using CellTracker™ (Invitrogen) prior to NaIO₄ oxidation according to the manufacturer's instructions.


Optimisation Experiments

Cell aggregation was performed following the procedures previously reported,⁴ but using the maltol-derived hydrazide **6** and HT29 cells and optimised using the following procedures.

1. Cells were prepared and plated as previously described except with either varying concentrations of Fe^{3+} or different agitation times in agarose-coated six-well plates with a final volume of 2 mL.
2. Three randomly selected images were taken at each time-point and the apparent aggregate area calculated using the area function in ImageJ,⁵ which was calibrated in micrometers using the microscope image dimensions.
3. The average apparent aggregate area \pm standard error of each time-point from three independent experiments was then calculated and plotted using Microsoft Excel and the data shown in **Fig. 2**.

Experimental

3-(Benzyloxy)-2-methyl-4*H*-pyran-4-one (**2**)^{6,7}




Following the procedure previously reported,⁶ sodium hydroxide (6 g, 0.15 mol) in water (20 mL) was added to a stirred solution of maltol **1** (17.8 g, 0.14 mol) in MeOH (180 mL), followed by benzyl chloride (20.9 g, 0.16 mol) and the mixture was heated to reflux for 12 h. The solvent was partially removed under reduced pressure to afford an orange oil which was dissolved in CH₂Cl₂ (80 mL) and washed with 5% (w/v) aqueous sodium hydroxide (5 x 30 mL) and water (2 x 50 mL). The organic fraction was dried over anhydrous sodium sulfate and filtered. The solvent was removed by rotary evaporation to give the benzylated product **2** as a pale yellow oil (26.3 g, 87%).

R_f [PE-EtOAc 4:6] 0.65; **IR** ν_{max} (film)/cm⁻¹ 1633, 1431 and 1173; **¹H NMR** δ_{H} (500 MHz; CDCl₃); 2.09 (3 H, s, CH₃), 5.16 (2 H, s, Bn CH₂), 6.36 (1 H, d, *J* 5.0 Hz, COCH=CH), 7.33-7.39 (5 H, m, Ph CH) and 7.59 (1 H, d, *J* 5.0, COCH=CH); **¹³C NMR** δ_{C} (125 MHz; CDCl₃); 14.8 (CH₃), 73.6 (CH₂), 117.2 (CH), 128.3 (CH), 128.4 (CH), 129.0 (CH), 136.9 (Cq), 143.8 (Cq), 153.4 (Cq), 159.7 (CH) and 175.1 (Cq); **MS** *m/z* (ES⁺) Found 217.0861 (MH⁺), C₁₃H₁₃O₃ (MH⁺) requires 217.0865.

Consistent with the ¹H NMR data previously reported for this compound.⁸


3-(3-(Benzyloxy)-2-methyl-4-oxopyridin-1(4H)-yl)propanoic acid (**3**)^{6,7}



Following the procedure previously reported,⁶ except using twice the amount of β -alanine and using a different work-up, β -alanine (8.7 g, 97.8 mmol) was added to a stirred solution of benzylated maltol **1** (8.5 g, 39.4 mmol) in EtOH (100 mL) and water (100 mL), followed by 10 M sodium hydroxide solution until pH 13 was achieved. After heating at reflux for 18 h, the solvent was partially removed under reduced pressure and water was added followed by hydrochloric acid to adjust to pH 4. The yellow precipitate was filtered and dried to afford the acid **3** as a pale yellow solid (7.9 g, 70%).

R_f [CH₂Cl₂-MeOH 9:1] 0.21; **Mp** 172-173 °C (EtOH), (Lit.⁶ 170-171 °C); **IR** ν_{max} (film)/cm⁻¹ 1729, 1625 and 1550; **¹H NMR** δ_{H} (500 MHz; DMSO); 2.21 (3 H, s, CH₃), 2.66 (2 H, t, *J* 7.0 Hz, NCH₂CH₂), 4.11 (2 H, t, *J* 7.0 Hz, NCH₂CH₂), 5.00 (2 H, s, Bn CH₂), 6.20 (1 H, d, *J* 7.5 Hz, COCH=CH), 7.32-7.41 (5 H, m, Ph CH) and 7.66 (1 H, d, *J* 7.5 Hz, COCH=CH); **¹³C NMR** δ_{C} (125 MHz; DMSO); 12.0 (CH₃), 34.5 (CH₂), 48.6 (CH₂), 72.0 (CH₂), 115.9 (CH), 122.1 (Cq), 127.9 (CH), 128.3 (CH), 128.4 (CH), 137.7 (Cq), 139.8 (CH), 145.0 (Cq), 171.9 (Cq) and 172.0 (Cq); **MS** *m/z* (ES⁺) Found 288.1238 (MH⁺) and 310.1055 (MNa⁺), C₁₆H₁₈N₁O₄ (MH⁺) requires 288.1236 and C₁₆H₁₇N₁NaO₄ (MNa⁺) requires 310.1055.


Methyl 3-(3-(benzyloxy)-2-methyl-4-oxopyridin-1(4*H*)-yl)propanoate (**4**)⁷



Acetyl chloride (0.23 g, 3.0 mmol) was added dropwise to a stirred solution of MeOH (5.0 mL) on ice, the solution was then allowed to warm to rt. The acid **3** (0.57 g, 2.0 mmol) was dissolved in MeOH (5 mL) and added dropwise to the solution and the reaction heated to reflux for 1 h. After 1 h the solvent was removed under reduced pressure to afford, after recrystallisation from MeOH, the methyl ester **4** as a white solid (0.59 g, 98%).

R_f [CH₂Cl₂-MeOH 9:1] 0.61; **Mp** 144-145 °C (MeOH); **IR** ν_{\max} (film)/cm⁻¹ 1742, 1633, 1186; **¹H NMR** δ_{H} (500 MHz; CDCl₃); 2.09 (3 H, s, CH₃), 2.63 (2 H, t, *J* 7.0 Hz, NCH₂CH₂), 3.70 (3 H, s, OCH₃), 4.08 (2 H, t, *J* 7.0 Hz, NCH₂CH₂), 5.21 (2 H, s, Bn CH₂), 6.42 (1 H, d, *J* 7.5 Hz, COCH=CH) and 7.27-7.40 (6 H, m, Ph CH and COCH=CH); **¹³C NMR** δ_{C} (125 MHz; CDCl₃); 12.4 (CH₃), 34.8 (CH₂), 48.9 (CH₂), 52.3 (OCH₃), 73.0 (CH₂), 117.5 (CH), 128.0 (CH), 128.2 (CH), 129.1 (CH), 137.5 (Cq), 138.4 (CH), 140.2 (Cq), 146.2 (Cq), 170.3 (Cq) and 173.4 (Cq); **MS** *m/z* (ES⁺) Found 324.1201 (MNa⁺), C₁₇H₁₉N₁NaO₄ (MNa⁺) requires 324.1212.


3-(3-(Benzyloxy)-2-methyl-4-oxopyridin-1(4H)-yl)propanehydrazide (5)



Hydrazine monohydrate (0.64 g, 12.8 mmol) was added to a stirred solution of the methyl ester **4** (1.5 g, 5.0 mmol) in MeOH (10 mL) at room temperature and heated at reflux for 18 h. After 18 h the solvent was removed under reduced pressure and the residue purified by column chromatography with silica gel using CH₂Cl₂:MeOH 2:8 solvent system to afford the protected hydrazide product **5** as a pale yellow solid (0.93 g, 62%).

R_f [CH₂Cl₂-MeOH 9:1] 0.09; **M.p** 76-78 °C (MeOH); **IR** ν_{\max} (film)/cm⁻¹ 1664, 1629 and 1127; **¹H NMR** δ_{H} (400 MHz; DMSO); 2.27 (3 H, s, CH₃), 2.48 (2 H, t, *J* 7.0 Hz, NCH₂CH₂), 4.15 (2 H, t, *J* 7.0 Hz, NCH₂CH₂), 4.38 (2 H, br s, NH₂), 5.07 (2 H, s, Bn CH₂), 6.18 (1 H, d, *J* 7.5 Hz, COCH=CH), 7.37-7.48 (5 H, m, Ph CH), 7.57 (1 H, d, *J* 7.5 Hz, COCH=CH) and 9.16 (1 H, s, NH); **¹³C NMR** δ_{C} (125 MHz; DMSO); 11.9 (CH₃), 34.3 (CH₂), 49.2 (CH₂), 71.9 (CH₂), 116.0 (CH), 116.1 (CH), 127.9 (CH), 128.3 (CH), 137.8 (Cq), 139.6 (CH), 140.8 (Cq), 145.3 (Cq), 168.2 (Cq) and 171.8 (Cq); **MS** *m/z* (ES⁺) Found 302.1480 (MH⁺) and 324.1310 (MNa⁺), C₁₆H₂₀N₃O₃ (MH⁺) requires 302.1505 and C₁₆H₁₉N₃NaO₃ (MNa⁺) requires 324.1324.

3-(3-Hydroxy-2-methyl-4-oxopyridin-1(4*H*)-yl)propanehydrazide (**6**)



The benzyl protected maltol hydrazide **5** (0.93 g, 3.1 mmol) was added to a stirred solution of 10% w/w Pd/C (0.62 mg, 20 mol%) in MeOH (10 mL). Air was purged and the reaction placed under a balloon of H₂ and stirring continued at room temperature for 24 h. The solution was filtered through filter paper and cotton wool and the solvent removed under reduced pressure to give, after recrystallisation from MeOH, the maltol hydrazide **6** as a beige coloured solid (0.55 g, 84%).

R_f [CH₂Cl₂-MeOH 9:1] 0.06; **Mp** 102-104°C (MeOH); **IR** ν_{\max} (film)/cm⁻¹ 3616, 1668 and 1626; **¹H NMR** δ_{H} (500 MHz; DMSO); 2.35 (3H, s, CH₃), 2.56 (2 H, t, *J* 7.0 Hz, NCH₂CH₂), 4.26 (2 H, t, *J* 7.0 Hz, NCH₂CH₂), 5.50-7.00 (3H, br s, NH and NH₂), 6.38 (1 H, d, *J* 7.0 Hz, COCH=CH), 7.65 (1 H, d, *J* 7.0 Hz, COCH=CH) and 9.71 (1 H, br s, OH); **¹³C NMR** δ_{c} (125 MHz; DMSO); 11.6 (CH₃), 34.1 (CH₂), 49.8 (CH₂), 110.7 (CH), 131.8 (Cq), 137.9 (CH), 144.8 (Cq), 166.6 (Cq) and 168.2 (Cq); **MS** *m/z* (ES⁺) Found 212.1033 (MH⁺) and 234.0838 (MNa⁺), C₉H₁₄N₃O₃ (MH⁺) requires 212.1035 and C₉H₁₃N₃NaO₃ (MNa⁺) requires 234.0855.

Acknowledgements


We wish to thank Dr Timothy J. Woodman, Dr Anneke Lubben and Dr Pauline J. Wood (University of Bath) for their assistance with the NMR, mass spectra and cell work, respectively. We are extremely grateful to the University of Bath for providing a studentship for AC and also wish to acknowledge RCUK and the University of Bath for the fellowship to LC.


References

1. M. Jost and U. Rodeck, in *Methods in Molecular Biology*, ed. K. Turksen, 2004, vol. 289, pp. 23-28.
2. A. H. Cory, T. C. Owen, J. A. Barltrop and J. G. Cory, *Cancer Commun.*, 1991, **3**, 207-212. MTS is 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium.
3. A. Ciupa, N. J. Griffiths, S. K. Light, P. J. Wood and L. Caggiano, *Med. Chem. Commun.*, 2011, **2**, 1011-1015.
4. P. A. De Bank, Q. Hou, R. M. Warner, I. V. Wood, B. E. Ali, S. MacNeil, D. A. Kendall, B. Kellam, K. M. Shakesheff and L. D. K. Buttery, *Biotechnol. Bioeng.*, 2007, **97**, 1617-1625.
5. ImageJ available from <http://rsb.info.nih.gov/ij/>.
6. P. S. Dobbin, R. C. Hider, A. D. Hall, P. D. Taylor, P. Sarpong, J. B. Porter, G. Xiao and D. van der Helm, *J. Med. Chem.*, 1993, **36**, 2448-2458.
7. B. L. Rai, L. S. Dekhordi, H. Khodr, Y. Jin, Z. Liu and R. C. Hider, *J. Med. Chem.*, 1998, **41**, 3347-3359.
8. Y.-L. Chen, D. J. Barlow, X.-L. Kong, Y.-M. Ma and R. C. Hider, *Dalton Trans.*, 2012, **41**, 10784-10791.

Supplementary Data and Images

¹H and ¹³C NMR Spectra






```

NAME      AC05-13-c
EXPNO    10
PROCNO   1
Date_    20111116
Time     12.47
INSTRUM  spect
PROBHD   5 mm PABBO BB-
PULPROG  zg30
TD        65536
SOLVENT  CDCl3
NS        16
DS        2
SWH       10330.578 Hz
FIDRES    0.157632 Hz
AQ        3.1719923 sec
RG        228
DW        48.400 usec
DE        13.94 usec
TE        295.2 K
D1        1.00000000 sec
TD0       1

----- CHANNEL f1 -----
NUC1     1H
P1       10.30 usec
PL1      -0.12 dB
PL1W     19.35150909 W
SF01     500.1330885 MHz
SI        32768
SF       500.1330138 MHz
WDW       EM
SSB       0
LB        0.30 Hz
GB        0
PC        1.00
    
```




```


NAME      AC05-13-c
EXPNO    11
PROCNO   1
Date_    20111116
Time     12.50
INSTRUM  spect
PROBHD   5 mm PABBO BB-
PULPROG  zgpg30
TD        65536
SOLVENT  CDCl3
NS        1024
DS        4
SWH       29761.904 Hz
FIDRES    0.454131 Hz
AQ        1.1010548 sec
RG        2050
DW        16.800 usec
DE        8.43 usec
TE        295.7 K
D1        2.00000000 sec
D11       0.03000000 sec
TD0       1



----- CHANNEL f1 -----
NUC1     13C
P1       9.50 usec
PL1      -0.51 dB
PL1W     99.92730713 W
SF01     125.7703643 MHz

----- CHANNEL f2 -----
CFDPRG2  waltz16
NUC2     1H
PCPD2    80.00 usec
PL2      -0.12 dB
PL12     17.94 dB
PL13     21.00 dB
PL2W     19.35150909 W
PL12W    0.30249262 W
PL13W    0.14352536 W
SF02     500.1320005 MHz
SI        32768
SF       125.7577938 MHz
WDW       EM
SSB       0
LB        1.00 Hz
GB        0
PC        1.40
    
```




AC05:27






MTS Assays – Hydrazone 6

HT29 Human Colon Carcinoma
3 Day Exposure MTS
Hydrazone 6




HT29 Human Colon Carcinoma
3 Day Exposure MTS
Hydrazone 6



1% DMSO only
Points are means \pm s.d
n = 4

1% DMSO only
Points are means \pm s.d
n = 4

MDA231 Human Breast Carcinoma
3 Day Exposure MTS
Hydrazone 6



1% DMSO only
Points are means \pm s.d
n = 4

HT29 cell Aggregation Experiments




Fig. S1.1 HT29 cell aggregation experiments – supplementary images 1. Representative images of unmodified (A) and maltol-modified (B) HT29 cells in the absence and presence of 50 μM FeCl_3 . Scale bars = 400 μm . These are additional images to those provided in **Fig. 1**, which only showed the last series of images (B+ Fe^{3+}) from this set of experiments.




Fig. S1.2 HT29 cell aggregation experiments – supplementary images 2. Representative images of unmodified (A) and maltol-modified (B) HT29 cells in the absence and presence of 50 μM FeCl_3 . Scale bars = 400 μm . These are additional images to those provided in **Fig. 1**.




Fig. S1.3 HT29 cell aggregation experiments – supplementary images 3. Representative images of unmodified (A) and maltol-modified (B) HT29 cells in the absence and presence of 50 μM FeCl_3 . Scale bars = 400 μm . These are additional images to those provided in **Fig. 1**.




Fig. S2 Extended HT29 cell aggregation experiments. Representative images of unmodified (A) and maltol-modified (B) HT29 cells in the absence and presence of 50 μM FeCl₃. Cells were prepared as described above in the General Experimental, Cell Aggregation, except (point 2) the cells were incubated with a 400 μM maltol hydrazide **6** solution in PBS. +xs Maltol = a PBS solution of maltol (10-fold excess) was added at the 120min time-point and left for 60mins. The images shown are at 180mins from the start of the experiment. Scale bars = 400 μm.

Metal Screen




Fig. S3 Metal screen – supplementary images 1, 2 and 3. Representative images of unmodified (A) and maltol-modified (B) HT29 cells in the presence of 50 μM of MCl_x after 20 mins agitation. Scale bars = 400 μm.

HT29 and MDA-MD-231 cell Aggregation Experiments




Fig. S4 HT29 and MDA-MD-231 cell aggregation experiments - supplementary images from different experiments. Representative fluorescence images of maltol-modified HT29 cells (green, B) and MDA-MB-231 cells (red, C) in the presence of 50 μM Fe^{3+} after 20 mins incubation. Scale bars = 200 μm . These are additional images to those provided in **Fig. 4**.